Biologiske antireumatika til gravide og ammende kvinder eller mandlige partnere
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Dokumenter
- Fulltext
Forlagets udgivne version, 1,42 MB, PDF-dokument
Effective medical treatment of rheumatic diseases during pregnancy and lactation is important, but the evidence for use of biological disease-modifying anti-rheumatic drugs (bDMARDs) is sparse and recommendations conflicting, which we discuss in this review. While some tumour necrosis factor (TNF)-α inhibitors appear safe during pregnancy and lactation, the evidence for use of non-TNF-α inhibitors is still too sparse to exclude adverse pregnancy outcomes and harm to the lactating child. The limited evidence on paternal exposure indicates, that TNF-α inhibitors do not affect male fertility or harm offspring. For non-TNF-α inhibitors, the evidence is still insufficient to draw any conclusion.
Bidragets oversatte titel | Biological disease-modifying anti-rheumatic drugs for pregnant and lactating women or male partners |
---|---|
Originalsprog | Dansk |
Artikelnummer | V06200479 |
Tidsskrift | Ugeskrift for Laeger |
Vol/bind | 183 |
Udgave nummer | 8 |
Antal sider | 7 |
ISSN | 0041-5782 |
Status | Udgivet - 22 feb. 2021 |
- Antirheumatic Agents/therapeutic use, Child, Female, Humans, Lactation, Male, Pregnancy, Pregnancy Outcome, Rheumatic Diseases/drug therapy
Forskningsområder
Links
- https://content.ugeskriftet.dk/sites/default/files/scientific_article_files/2021-02/v06200479_web.pdf
Forlagets udgivne version
ID: 305547721